---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-028226"
form_type: "8-K"
ticker: "DERM"
cik: "0001867066"
company_name: "Journey Medical Corp"
filed_at: "2025-03-26T23:59:59+00:00"
generated_at: "2026-05-24T05:14:59.814143+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Journey Medical reports FY2024 revenue $56.1M, net loss $14.7M; Emrosi launch underway

## Summary
- Total revenue $56.1M, down 29% YoY; product revenue net $55.1M (-8%) due to higher rebates and lower legacy volumes.
- Net loss $14.7M ($0.72/sh) vs $3.9M loss prior year; adjusted EBITDA $0.8M vs $15.6M.
- FDA approved Emrosi (minocycline) for rosacea Nov 2024; distribution started, first prescriptions filled, full promo expected April 2025.
- Met all 2024 financial guidance: product revenue $55-60M, SG&A $39-42M, R&D $9-10M.
- Non-GAAP adjusted EBITDA per share $0.04 basic, $0.03 diluted.

## SEC filing metadata
- accession: 0001104659-25-028226
- form_type: 8-K
- ticker: DERM
- cik: 0001867066
- company_name: Journey Medical Corp
- filed_at: 2025-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867066/000110465925028226/0001104659-25-028226-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867066/000110465925028226/tm2510555d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-028226
- JSON: https://secwatch.observer/filing/0001104659-25-028226.json
- Plain text: https://secwatch.observer/filing/0001104659-25-028226.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.